Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shengdi Su"'
Autor:
Chen Ning, Shengdi Su, Jiaming Li, Dexuan Kong, Hui Cai, Zhiying Qin, Han Xing, Xijing Chen, Jiake He
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The objective of the present study was to identify the mechanism of RSV–CP DDI and e
Externí odkaz:
https://doaj.org/article/ce1fa347c56a40e2b3674eba8499294f
Autor:
Chang Ren, Yao Wang, Mei Zhang, Dexuan Kong, Chen Ning, Yujie Cheng, Yueying Bian, Mengqi Sun, Shengdi Su, Yucong Wang, Yongjie Zhang, Yang Lu, Ning Li, Di Zhao, Xijing Chen
Publikováno v:
Pharmaceutical Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c802781670403bb059d987d84498eb34
https://doi.org/10.1007/s11095-023-03489-x
https://doi.org/10.1007/s11095-023-03489-x
Autor:
Dexuan Kong, Chen Ning, Yueying Bian, Ning Li, Di Zhao, Mengqi Sun, Yucong Wang, Yao Wang, Xijing Chen, Yongjie Zhang, Yang Lu, Yujie Cheng, Chang Ren, Shengdi Su, Mei Zhang
Publikováno v:
Pharmaceutical Research. 38:1847-1862
Sulcardine sulfate (Sul) is a novel antiarrhythmic agent with promising pharmacological properties, which is currently being evaluated in several clinical trials as an oral formulation. To meet the medication needs of patients with acute conditions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87456166bce764e8b6b0f99cc09939e2
https://doi.org/10.1007/s11095-021-03128-3
https://doi.org/10.1007/s11095-021-03128-3
Autor:
Jialin Chen, Wujun Wang, Yue Wang, Xiushuang Yuan, Chengzhi He, Pengfei Pei, Shengdi Su, Weihong Zhao, Shi-Zhong Luo, Long Chen
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 179
Water insolubility poses a significant challenge in the clinical applications of many small molecule drugs. To improve the drug delivery efficiency, two branched amphiphilic peptides (BAPs) were designed in a computer-aided manner, for drug-loading t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee40c114772f66881b82aebce6b1b3e
https://pubmed.ncbi.nlm.nih.gov/36096399
https://pubmed.ncbi.nlm.nih.gov/36096399
Autor:
Chang, Ren, Yao, Wang, Mei, Zhang, Dexuan, Kong, Chen, Ning, Yujie, Cheng, Yueying, Bian, Mengqi, Sun, Shengdi, Su, Yucong, Wang, Yongjie, Zhang, Yang, Lu, Ning, Li, Di, Zhao, Xijing, Chen
Publikováno v:
Pharmaceutical research. 38(11)
Sulcardine sulfate (Sul) is a novel antiarrhythmic agent with promising pharmacological properties, which is currently being evaluated in several clinical trials as an oral formulation. To meet the medication needs of patients with acute conditions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a438a3540bef0257b05a7ad6ac94900
https://pubmed.ncbi.nlm.nih.gov/34773182
https://pubmed.ncbi.nlm.nih.gov/34773182
Autor:
Chen Feng, Etienne Empweb Anger, Xiong Zhang, Shengdi Su, Chenlin Su, Shuxin Zhao, Feng Yu, Ji Li
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 7; Pages: 3674
Aristolochic acid I (AA I) is one of the most abundant and toxic aristolochic acids that is reported to cause Aristolochic acid nephropathy (AAN). This paper was designed to assess whether mitochondrial Uncoupling Protein 2 (UCP2), which plays an ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4644d34b880922e40a7148911a474380
https://doi.org/10.3390/ijms23073674
https://doi.org/10.3390/ijms23073674
Publikováno v:
Results in Engineering, Vol 20, Iss , Pp 101450- (2023)
This paper introduces various preparation methods for nanoporous membranes composed of zinc oxide composites and addresses the low light transmittance issue commonly associated with existing methods. A nanoporous composite membrane, which utilizes PE
Externí odkaz:
https://doaj.org/article/3ce4f873b1be4c9cbc6a0c7c6fc2fc30